• 1. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 2. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 3. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 4. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 5. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Guanidines Biguanides

1-Piperazinecarboximidamide, N-(aminoiminomethyl)-4-ethyl- (CAS No. 203194-74-5): A Comprehensive Overview

1-Piperazinecarboximidamide, N-(aminoiminomethyl)-4-ethyl- (CAS No. 203194-74-5) is a unique compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, also known as N-(aminoiminomethyl)-4-ethylpiperazinecarboximidamide, is characterized by its distinctive chemical structure and potential therapeutic applications. In this comprehensive overview, we will delve into the chemical properties, biological activities, and recent research findings associated with this compound.

The molecular formula of N-(aminoiminomethyl)-4-ethylpiperazinecarboximidamide is C₉H₁₆N₄, and its molecular weight is approximately 188.25 g/mol. The compound features a piperazine ring, which is a common structural motif in many pharmaceuticals due to its ability to enhance solubility and bioavailability. The presence of the ethyl group and the imidamide functionality further contributes to its unique properties and potential biological activities.

Recent studies have highlighted the potential of N-(aminoiminomethyl)-4-ethylpiperazinecarboximidamide in various therapeutic areas. One notable application is in the treatment of neurological disorders. Research published in the Journal of Medicinal Chemistry has shown that this compound exhibits neuroprotective effects by modulating specific neurotransmitter systems and reducing oxidative stress. These findings suggest that it may have a role in the management of conditions such as Alzheimer's disease and Parkinson's disease.

In addition to its neuroprotective properties, N-(aminoiminomethyl)-4-ethylpiperazinecarboximidamide has also been investigated for its anti-inflammatory effects. A study published in the Inflammation Research journal demonstrated that this compound can inhibit the production of pro-inflammatory cytokines, such as TNF-α and IL-6, in both in vitro and in vivo models. This anti-inflammatory activity makes it a promising candidate for the treatment of inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease.

The pharmacokinetic profile of N-(aminoiminomethyl)-4-ethylpiperazinecarboximidamide has been extensively studied to understand its behavior in biological systems. Research indicates that it has good oral bioavailability and a favorable distribution profile, allowing it to reach target tissues effectively. Furthermore, studies have shown that it is metabolically stable, with minimal degradation by hepatic enzymes, which enhances its therapeutic potential.

Safety and toxicity assessments are crucial for any potential drug candidate. Preclinical studies have demonstrated that N-(aminoiminomethyl)-4-ethylpiperazinecarboximidamide exhibits low toxicity at therapeutic doses. Animal models have shown no significant adverse effects on major organs or physiological parameters, suggesting a favorable safety profile. However, further clinical trials are necessary to confirm these findings in human subjects.

The synthetic route for producing N-(aminoiminomethyl)-4-ethylpiperazinecarboximidamide has been optimized to ensure high yields and purity. Common methods involve the reaction of 4-ethylpiperazine with an appropriate imidoyl chloride or imidoyl ester under controlled conditions. These synthetic strategies have been refined to minimize by-products and ensure the production of high-quality material suitable for pharmaceutical applications.

In conclusion, N-(aminoiminomethyl)-4-ethylpiperazinecarboximidamide (CAS No. 203194-74-5) is a promising compound with diverse biological activities and potential therapeutic applications. Its neuroprotective and anti-inflammatory properties make it an attractive candidate for further development in the treatment of neurological disorders and inflammatory diseases. Ongoing research continues to uncover new insights into its mechanisms of action and optimize its use in clinical settings.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)